BioDelivery Sciences (BDSI) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
March 15, 2018 4:01 PM EDTFull-year 2017 net revenue of $62.0 million vs. $15.5 million in 2016
BELBUCA® fourth quarter 2017 net revenue of $9.4 million vs. $6.4 million in third quarter; an increase of 47%
BELBUCA prescription growth of 84% in 2017 over 2016
Preferred coverage for BELBUCA secured with Humana, the second largest Medicare insurer in the country, effective March 1
BELBUCA launched in Canada in January by commercial partner Purdue (Canada)
Conference Call Today at 4:30 PM Eastern Time
RALEIGH, N.C., March 15, 2018 (GLOBE NEWSWIRE)... More
